Scarica l'app Stockscreener
1.17
9.30%
-0.12
Dopo l'orario di chiusura:
1.15
-0.02
-1.71%
Precedente Chiudi:
$1.29
Aprire:
$1.28
Volume 24 ore:
747.37K
Relative Volume:
1.51
Capitalizzazione di mercato:
$42.88M
Reddito:
-
Utile/perdita netta:
$-9.16M
Rapporto P/E:
-2.0526
EPS:
-0.57
Flusso di cassa netto:
$-8.75M
1 W Prestazione:
+4.46%
1M Prestazione:
-7.14%
6M Prestazione:
+13.59%
1 anno Prestazione:
+15.29%
Intervallo 1D:
$1.14
$1.30
Intervallo di 1 settimana:
$1.05
$1.30
Portata 52W:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Nome
Renovorx Inc
Settore
Industria
Telefono
408-800-2649
Indirizzo
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Confronta RNXT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.17 | 39.94M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Renovorx Inc Borsa (RNXT) Ultime notizie
Has RenovoRx Inc. formed a bullish divergence2025 Volatility Report & Risk Managed Investment Signals - newser.com
What does recent volatility data suggest for RenovoRx Inc.Market Trend Summary & High Accuracy Swing Trade Signals - newser.com
Evaluating RenovoRx Inc. with trendline analysisPortfolio Return Report & Long-Term Safe Investment Ideas - newser.com
Relative strength of RenovoRx Inc. in sector analysisQuarterly Growth Report & AI Forecast for Swing Trade Picks - newser.com
Is RenovoRx Inc. stock reversal real or fakeJuly 2025 Retail & AI Enhanced Trade Execution Alerts - newser.com
RenovoRx : Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD - MarketScreener
Is RenovoRx Inc. stock entering bullish territory2025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com
Is RenovoRx Inc. reversing from oversold territoryJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Identifying reversal signals in RenovoRx Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
RenovoRx Inc. stock chart pattern explainedMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com
Is RenovoRx Inc. forming a bottoming baseEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Will RenovoRx Inc. stock outperform Dow Jones indexAnalyst Upgrade & Risk Controlled Daily Trade Plans - newser.com
RenovoRx adds interventional oncology expert to scientific advisory board By Investing.com - Investing.com Nigeria
RenovoRx’s Earnings Call: Positive Outlook Amid Growth - MSN
RenovoRx adds interventional oncology expert to scientific advisory board - Investing.com
RenovoRx expands Scientific Advisory Board with appointment of Baere - TipRanks
RenovoRx Appoints Renowned Oncologist Thierry de Baère, MD, PhD, to Scientific Advisory Board - Quiver Quantitative
400+ publications & 22,000 citations: RenovoRx appoints Thierry de Baère to Scientific Advisory Board - Stock Titan
Will RenovoRx Inc. outperform the marketMarket Weekly Review & Intraday High Probability Setup Alerts - newser.com
Will earnings trigger a reversal in RenovoRx Inc.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Forecasting RenovoRx Inc. price range with options data2025 Investor Takeaways & Weekly Momentum Picks - newser.com
RenovoRx : Corporate Overview - MarketScreener
Custom strategy builders for tracking RenovoRx Inc.2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Developing predictive dashboards with RenovoRx Inc. dataEarnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
How institutional ownership impacts RenovoRx Inc. stock2025 Short Interest & Fast Gaining Stock Reports - newser.com
RenovoRx prices public offering to raise $12.1M - MSN
Comparing Annovis Bio (NYSE:ANVS) & RenovoRx (NASDAQ:RNXT) - Defense World
RenovoRx (NASDAQ:RNXT) Trading Up 7.6% – Here’s What Happened - Defense World
What analysts say about RenovoRx Inc stockCurrency Fluctuation Impact & Register for the Next Free Workshop - earlytimes.in
RenovoRx Inc Stock Analysis and ForecastTechnical Pattern Recognition & Budget Friendly Portfolio Growth - earlytimes.in
Renovorx Inc Azioni (RNXT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Renovorx Inc Azioni (RNXT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
| Agah Ramtin | Chief Medical Officer |
Jun 05 '25 |
Buy |
1.40 |
21,000 |
29,400 |
734,460 |
| Marton Laurence | Director |
May 02 '25 |
Option Exercise |
0.15 |
20,480 |
3,072 |
66,164 |
| Agah Ramtin | Chief Medical Officer |
Apr 15 '25 |
Buy |
0.90 |
15,000 |
13,500 |
1,113,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 15 '25 |
Buy |
0.91 |
7,500 |
6,821 |
320,040 |
| Agah Ramtin | Chief Medical Officer |
Apr 11 '25 |
Buy |
0.80 |
20,000 |
16,000 |
1,098,460 |
| Kocak Ron | VP Controller and PAO |
Apr 10 '25 |
Buy |
0.79 |
6,500 |
5,135 |
12,595 |
| Kocak Ron | VP Controller and PAO |
Apr 09 '25 |
Buy |
0.80 |
6,000 |
4,800 |
6,095 |
| Kocak Ron | VP Controller and PAO |
Apr 08 '25 |
Buy |
0.80 |
95 |
76 |
95 |
| Agah Ramtin | Chief Medical Officer |
Apr 09 '25 |
Buy |
0.81 |
30,000 |
24,399 |
1,078,460 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):